[go: up one dir, main page]

ES2091211T3 - Ranolazina y piperazinas relacionadas utilizadas en el tratamiento de tejidos que sufren una lesion fisica o quimica. - Google Patents

Ranolazina y piperazinas relacionadas utilizadas en el tratamiento de tejidos que sufren una lesion fisica o quimica.

Info

Publication number
ES2091211T3
ES2091211T3 ES90111787T ES90111787T ES2091211T3 ES 2091211 T3 ES2091211 T3 ES 2091211T3 ES 90111787 T ES90111787 T ES 90111787T ES 90111787 T ES90111787 T ES 90111787T ES 2091211 T3 ES2091211 T3 ES 2091211T3
Authority
ES
Spain
Prior art keywords
treatment
physical
ranolazine
chemical injury
tissues suffering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90111787T
Other languages
English (en)
Inventor
Robert J Dow
Pierre Ferrandon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Application granted granted Critical
Publication of ES2091211T3 publication Critical patent/ES2091211T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)

Abstract

DERIVADOS DE PIPERACINA, EN PARTICULAR RANOLACINA, QUE RESULTAN DE GRAN UTILIDAD EN EL TRATAMIENTO DE TEJIDOS QUE EXPERIMENTEN UNA AGRESION FISICA O QUIMICA, Y ESPECIFICAMENTE EN EL TRATAMIENTO DE CARDIOPLEJIAS Y HERIDAS HIPOXICAS Y/O DE REPERFUSION EN TEJIDO CARDIACO, OSEO, MUSCULAR O CEREBRAL, Y EN SU USO EN TRANSPLANTES.
ES90111787T 1989-06-23 1990-06-21 Ranolazina y piperazinas relacionadas utilizadas en el tratamiento de tejidos que sufren una lesion fisica o quimica. Expired - Lifetime ES2091211T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37043589A 1989-06-23 1989-06-23

Publications (1)

Publication Number Publication Date
ES2091211T3 true ES2091211T3 (es) 1996-11-01

Family

ID=23459660

Family Applications (3)

Application Number Title Priority Date Filing Date
ES90111787T Expired - Lifetime ES2091211T3 (es) 1989-06-23 1990-06-21 Ranolazina y piperazinas relacionadas utilizadas en el tratamiento de tejidos que sufren una lesion fisica o quimica.
ES95119463T Expired - Lifetime ES2177601T3 (es) 1989-06-23 1990-06-21 Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. .
ES95119452T Expired - Lifetime ES2182863T3 (es) 1989-06-23 1990-06-21 Ranolazina y piperazinas relacionadas para proteger musculos esqueleticos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES95119463T Expired - Lifetime ES2177601T3 (es) 1989-06-23 1990-06-21 Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. .
ES95119452T Expired - Lifetime ES2182863T3 (es) 1989-06-23 1990-06-21 Ranolazina y piperazinas relacionadas para proteger musculos esqueleticos.

Country Status (13)

Country Link
US (2) US5506229A (es)
EP (3) EP0407780B1 (es)
JP (1) JP3232085B2 (es)
AT (3) ATE218344T1 (es)
AU (1) AU633589B2 (es)
CA (1) CA2019580C (es)
DE (3) DE69034000T2 (es)
DK (3) DK0714660T3 (es)
ES (3) ES2091211T3 (es)
GR (1) GR3020976T3 (es)
IE (1) IE80710B1 (es)
NZ (2) NZ234184A (es)
ZA (1) ZA904842B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1051168B1 (en) * 1997-08-08 2006-03-01 Duke University Compositions for facilitating surgical procedures
US6711436B1 (en) 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
AU778203B2 (en) * 2000-02-18 2004-11-25 Gilead Sciences, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US6638970B2 (en) 2000-02-22 2003-10-28 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
AU2001238590A1 (en) 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
JP3980885B2 (ja) * 2000-02-22 2007-09-26 スィーヴィー セラピューティクス インコーポレイテッド 置換ピペラジン化合物
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
CA2420182A1 (en) * 2000-08-25 2002-03-07 Organ Recovery Systems, Inc. Methods of thrombolytic organ treatment and repair
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
GB0028414D0 (en) * 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
ES2523873T3 (es) * 2002-05-21 2014-12-02 Gilead Sciences, Inc. Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
ATE365737T1 (de) 2002-12-05 2007-07-15 Cv Therapeutics Inc Substituierte piperazinverbindungen undderen verwendung als fettsuureoxidationsinhibitoren
KR20050086956A (ko) 2003-01-03 2005-08-30 씨브이 쎄러퓨틱스, 인코포레이티드 치환된 복소환 화합물
US7026321B2 (en) 2003-01-17 2006-04-11 Cv Therapeutics, Inc. Substituted heterocyclic compounds
NZ544449A (en) 2003-06-23 2008-10-31 Cv Therapeutics Inc Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
WO2005061470A1 (en) 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
KR20070051305A (ko) * 2004-09-08 2007-05-17 씨브이 쎄러퓨틱스, 인코포레이티드 치환된 피페라진 화합물 및 지방산 산화 저해제로서의 이의용도
EP1809289A1 (en) * 2004-11-09 2007-07-25 Cv Therapeutics, Inc. Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
AU2006203890A1 (en) * 2005-01-06 2006-07-13 Gilead Sciences, Inc. Sustained release pharmaceutical formulations comprising ranolazine
EP1865945A4 (en) * 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd TREATMENT COMBINATION FOR ENDOTHELIAL DISORDERS, ANGINA AND DIABETES
WO2008101012A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
EP2117549A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
EP2216024A3 (en) 2007-02-13 2011-08-24 Cv Therapeutics, Inc. Use of Ranolazine for the treatment of cardiovascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
ES2402675T3 (es) * 2007-05-31 2013-05-07 Gilead Palo Alto, Inc. Ranolazina para el péptido natriurético de tipo cerebral a niveles elevados
US20090203707A1 (en) * 2008-02-06 2009-08-13 Sridharan Rajamani Methods for treating pain
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
EP2515880B1 (en) 2009-05-28 2019-11-27 Lupin Limited Novel pharmaceutical compositions of ranolazine
AU2010269111B2 (en) * 2009-07-09 2014-12-11 Ozteo Pty Ltd Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers
AU2015200961B2 (en) * 2009-07-09 2017-02-16 Ozteo Pty Ltd Treatment of Non-Neuronal and Non-Cardiac Cell, Tissue and Organ Damage and Associated Pain with Persistent Sodium Current Blockers
WO2011036677A2 (en) 2009-09-25 2011-03-31 Lupin Limited Sustained release composition of ranolazine
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
EP2717860A4 (en) * 2011-06-08 2014-11-05 Sti Pharma Llc FORMULATION FROM A WATER SOLUBLE AND PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND WITH CONTROLLED ABSORPTION FOR ONLY DAILY APPLICATION
KR101476379B1 (ko) * 2011-11-30 2014-12-29 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
KR101331186B1 (ko) * 2013-08-05 2013-11-22 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
JP2024537585A (ja) * 2021-09-27 2024-10-16 タスリー・ファーマシューティカル・グループ・カンパニー・リミテッド 心筋虚血の治療のための医薬組成物及びその製造方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry

Also Published As

Publication number Publication date
CA2019580C (en) 2007-03-27
EP0407780B1 (en) 1996-09-11
DE69033967D1 (de) 2002-07-11
NZ247044A (en) 1997-04-24
EP0719558B1 (en) 2002-06-05
US5906988A (en) 1999-05-25
DE69028457T2 (de) 1997-02-20
ATE218344T1 (de) 2002-06-15
IE902250A1 (en) 1991-01-16
ZA904842B (en) 1992-02-26
ATE142497T1 (de) 1996-09-15
DK0714660T3 (da) 2002-10-07
US5506229A (en) 1996-04-09
EP0714660A1 (en) 1996-06-05
EP0714660B1 (en) 2002-09-04
EP0719558A1 (en) 1996-07-03
NZ234184A (en) 1997-01-29
CA2019580A1 (en) 1990-12-23
DE69034000D1 (de) 2002-10-10
ES2177601T3 (es) 2002-12-16
AU633589B2 (en) 1993-02-04
DE69028457D1 (de) 1996-10-17
DE69033967T2 (de) 2002-12-19
DK0719558T3 (da) 2002-10-07
DK0407780T3 (da) 1996-09-30
ATE223218T1 (de) 2002-09-15
JP3232085B2 (ja) 2001-11-26
ES2182863T3 (es) 2003-03-16
EP0407780A3 (en) 1992-01-02
AU5761890A (en) 1991-01-03
JPH0348672A (ja) 1991-03-01
GR3020976T3 (en) 1996-12-31
DE69034000T2 (de) 2003-06-05
IE80710B1 (en) 1998-12-16
EP0407780A2 (en) 1991-01-16
IE902250L (en) 1990-12-23

Similar Documents

Publication Publication Date Title
ES2091211T3 (es) Ranolazina y piperazinas relacionadas utilizadas en el tratamiento de tejidos que sufren una lesion fisica o quimica.
FI20100200L (fi) Heteroaryylipiperidiinejä, -pyrrolidiinejä ja -piperatsiineja ja niiden käyttö antipsykoottisina ja analgeettisina aineina
ATE251140T1 (de) N-(2 oxoacetyl oder sulphonyl)- pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
GR3018541T3 (en) Condensed heterocyclic compounds and their use in therapy.
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
IT1209229B (it) Uso di composti perfluorocarburici per il trattamento di lesioni,articoli e composizioni contenenti detti composti
ZA908953B (en) Transdermal administration of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole
DE68905374D1 (de) Mittel zur vorbeugung und abhilfe gegen ischaemische verletzungen.
DE69001263D1 (de) Steife kautschukmischungen und artikel, die komponenten davon enthalten.
ITBO910163A1 (it) Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
ES2063202T3 (es) Nuevas 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y -tionas y su uso en la prevencion o tratamiento del sida.
ATE298339T1 (de) ß3,7-DIAZABICYCLO(3.3.0)OCTANE UND DEREN VERWENDUNG BEI DER BEHANDLUNG VON HERZRHYTHMUSSTÖRUNGENß
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
DK0397175T3 (da) Substituerede pyrrolizinforbindelser og deres anvendelse inden for farmacien
MX9302951A (es) Composicion farmaceutica para tratar la hiperproliferacion celular.
BG101126A (en) The use of muramylpeptide compounds
PE20000037A1 (es) Producto absorbente que tiene propiedades mejoradas de control de residuos corporales fluido viscosos
NO961204L (no) Triaryletylenderivater for anvendelse innen terapi
NO950248D0 (no) NG-monometyl-L-argininhydrokloridderivater og anvendelse derav for behandling av septisk sjokk
MXPA02012942A (es) Compuestos nuevos de bispidina y su uso en el tratamiento de arritmias cardiacas.
IT8819079A0 (it) Composizione conciante e sua utilizzazione nei procedimenti di concia e riconcia delle pelli animali.
NO923709L (no) Utstyr/hjelpemidler for engangsbruk, spesielt innen sykehus- og sanitetssektoren
IT8024862A0 (it) L'applicazione in terapeutica come agenti analgesici dei derivati del 4,5,6,7-tetraidroisossazolo (5,4-c)piridin-3-ol
Collins Design for use, design for the millions; proposals and options of the National Industrial Design Council 1948-1960.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 407780

Country of ref document: ES